Esketamine in Treatment-Resistant Depression: Evidence, Safety, and Practice-Building

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The expert psychiatrist examined structured programs such as inpatient, partial hospitalization, and intensive outpatient care, then described how electroconvulsive therapy and transcranial magnetic stimulation work.

Led by the moderator, the expert psychiatrist discusses the TRANSFORM and SUSTAIN trials as the strongest evidence for esketamine and notes that the requirement for a concomitant oral antidepressant has since been lifted.

Led by the moderator, the expert psychiatrist examined how he matches patients to each agent.

The expert psychiatrist examined safety as a layered process that begins with a trusting therapeutic relationship, continues with screening for medical contraindications and coordination with other clinicians, and extends to set, setting, and on-site emergency equipment.

Led by the moderator, the panelists discuss the legal, insurance credentialing, DEA licensure, REMS certification, and medication-acquisition steps behind opening a ketamine and esketamine practice, followed by staffing, systems, and outreach.

Led by the moderator, the panelists examined the rewards and demands of interventional care.

Led by the moderator, the panelists examine how to build a center that lasts.